Abstract
Major changes have occurred in therapeutics for coronavirus-19 (COVID-19) infection over the past 12-18 mo, most notably in early outpatient therapy. In most cases, solid organ transplant recipients were not included in the original clinical trials of these agents, so studies of real-world outcomes have been important in building our understanding of their utility. This review examines what is known about clinical outcomes in solid organ transplant recipients with newer therapies. SARS-CoV-2 monoclonal antibodies for early treatment or prophylaxis have likely prevented many hospitalizations and deaths. In addition, convalescent plasma, the oral drugs nirmatrelvir/ritonavir and molnupiravir, remdesivir for early outpatient treatment, anti-inflammatory therapy, and investigational virus-specific T-cell therapy will be discussed. Finally, the later consequences of COVID-19, such as secondary infections, long COVID symptoms, and persistent active infection, are identified as areas for future research.
【초록키워드】 COVID-19, Treatment, convalescent plasma, SARS-CoV-2, clinical trial, therapy, Hospitalization, molnupiravir, monoclonal antibody, Infection, Remdesivir, drug, outcome, Symptoms, Clinical outcome, Prophylaxis, COVID, early treatment, Research, utility, change, secondary infections, Therapies, solid organ transplant, deaths, Major, Anti-inflammatory therapy, recipient, consequence, occurred, addition, prevented, virus-specific T-cell, 【제목키워드】 COVID-19, Therapeutics, omicron, Transplant, Including, Solid,